Axcan Pharma Canasa
This article was originally published in Pharmaceutical Approvals Monthly
Mesalamine rectal suppositories are approved Jan. 5. At FDA's request, Axcan has been selling mesalamine suppositories as Fivasa since July 1999 on an emergency basis following a recall of Solvay's 5-ASA suppositories Rowasa. Axcan is planning to launch Canasa in April and expects approval for enema and tablet forms in 200
You may also be interested in...
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.
Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.